MedTrace Logo

CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

NCT07015801 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-06-11

No results posted yet for this study

Summary

Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).

Conditions

  • Cytomegalovirus Viremia
  • Cytomegalovirus Pneumonia
  • T-Lymphocyte Immunodeficiency

Interventions

BIOLOGICAL

CMV-VST

30-40 x 10\^3 viable CD3+ cells/kg

Sponsors & Collaborators

  • Alberta Precision Laboratories

    collaborator UNKNOWN

  • Alberta Health services

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • University of Calgary

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2027-04-30
Completion
2040-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07015801 on ClinicalTrials.gov